Although BTK inhibitors have shown promising efficacy and have become the standard of care for treating chronic lymphocytic leukemia, mantle cell lymphoma, and marginal zone B-cell lymphoma as single agents5, the efficacy of BTK inhibitor monotherapy for aggressive large B-cell lymphoma has not been satisfactory. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.